Liu Q C, Zheng B R, Zhang C L
Langfang Institute of Hematology, Hebei.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1995 Apr;15(4):198-201.
The testing kit of second generation for serum anti-HCV was used in 82 cases of aplastic anemia (AA). The results showed that positive rate was 69.4% (43/62) in the patients of AA with transfusion, this was significantly higher than that in the patients of AA without transfusion. There was no difference of anti-HCV antibody positive rate between chronic AA and acute AA (P > 0.05), incidence rate of post-transfusion hepatitis C (PTHC) in AA was 33.9% (21/62), among which the incidence rate in acute and chronic AA were 68.8% (11/16) and 21.7% (10/46) respectively (P < 0.01). The anti-HCV positive patients were divided into two groups: PTHC and non-PTHC, there was no statistical difference of their transfusion volume, hemoglobin, white blood cell between these groups. Response rate of AA was lower in anti-HCV positive patients than that in negative patients (P < 0.05). Acute, icteric PTHC was predominant in patients with AA. The patients with AA complicated with PTHC was liable to bleed and be infected. PTHC has been an important complication in patients with AA. The better response was obtained by TCM-WM therapy in the patients.
应用第二代血清抗丙型肝炎病毒（HCV）检测试剂盒检测82例再生障碍性贫血（AA）患者。结果显示，有输血史的AA患者抗-HCV阳性率为69.4%（43/62），显著高于无输血史的AA患者。慢性AA与急性AA患者抗-HCV抗体阳性率差异无统计学意义（P>0.05），AA患者输血后丙型肝炎（PTHC）发病率为33.9%（21/62），其中急性AA和慢性AA的发病率分别为68.8%（11/16）和21.7%（10/46）（P<0.01）。将抗-HCV阳性患者分为PTHC组和非PTHC组，两组间输血量、血红蛋白、白细胞差异无统计学意义。抗-HCV阳性的AA患者缓解率低于阴性患者（P<0.05）。AA患者中急性、黄疸型PTHC为主。AA合并PTHC患者易出血和感染。PTHC已成为AA患者的重要并发症。中西医结合治疗该类患者疗效较好。
